A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease

Table 1

Baseline characteristics of the 7 randomized controlled trials included in this meta-analysis comparing the treatment effects of PPIs once daily versus twice daily for GERD patients.

Author	Country	Participants	Duration	Age (mean or mean ± SD, y)	Male (%)	Weight (kg) or BMI	Intervention
Orlando et al. 2010	USA	368	4 weeks	43.7	46.3%	29.2	Esomeprazole 20 mg QD
				43.9	42.1%	29.8	Esomeprazole 40 mg QD
				46.9	38.1%	30.5	Esomeprazole 40 mg BID
Delchier et al. 2000	Europe	310	8 weeks	55 ± 15.7	55%	N	Rabeprazole 20 mg QD
				52 ± 14.3	70%	N	Rabeprazole 10 mg BID
				53 ± 15.1	61%	N	Omeprazole 20 mg QD
Fass et al. 2006	USA	328	8 weeks	49 ± 12.5	40.6%	86.9 ± 19.7	Esomeprazole 40 mg QD
				48.3 ± 13.6	45.8%	87.5 ± 19.2	Lansoprazole 30 mg BID
Kinoshita and Hongo 2012	Japan	337	8 weeks	64.5 ± 13.9	51.8%	24.14 ± 3.61	Rabeprazole 20 mg QD
				65.5 ± 13.3	46.8%	24.89 ± 3.68	Rabeprazole 10 mg BID
				66.6 ± 13.8	44.1%	24.32 ± 4.04	Rabeprazole 20 mg BID
Chen et al. 2010	Taiwan	200	8 weeks	42.6	63.36%	27.9 ± 2	Pantoprazole 40 mg QD
				43.1	56.43%	28.2 ± 2.1	Pantoprazole 40 mg BID
Vasiliadis et al. 2010	Greece	75	30 days	40.96 ± 11.98	70.8%	26.6 ± 0.97	Esomeprazole 40 mg BID
				44.17 ± 11.18	75%	27.2 ± 0.87	Esomeprazole 40 mg QD
				42.68 ± 11.34	72%	26.8 ± 1.17	Esomeprazole 40 mg QOD
Galmiche et al. 2001	France	92	1 week	42.1 ± 14.3	63.64%	N	Rabeprazole 10 mg BID
				39.4 ± 13.8	66.67%	N	Rabeprazole 20 mg QD
				41.2 ± 14.2	73.91%	N	Omeprazole 20 mg QD
				43.6 ± 11.3	52.17%	N	Placebo